An investigation for investors in NASDAQ:CYNA shares was announced concerning whether the takeover of Cynapsus Therapeutics Inc by Sunovion Pharmaceuticals Inc for $40.50 per share is unfair to NASDAQ:CYNA stockholders.
Investors who purchased shares of Cynapsus Therapeutics Inc (NASDAQ:CYNA) and currently hold any of those NASDAQ:CYNA shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain officers and directors of Cynapsus Therapeutics Inc breached their fiduciary duties owed to NASDAQ:CYNA investors in connection with the proposed acquisition.
On August 31, 2016, Sunovion Pharmaceuticals Inc. (Sunovion) and Cynapsus Therapeutics Inc (NASDAQ:CYNA) (TSX: CTH) announced that the companies have signed an agreement under which Sunovion Pharmaceuticals Inc. will acquire Cynapsus for US$40.50 per share in cash.
However, the investigation concerns whether the offer is unfair to NASDAQ:CYNA stockholders. More specifically, the investigation concerns whether the Cynapsus Therapeutics Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders’ best interests in connection with the proposed sale.
Shares of Cynapsus Therapeutics Inc (NASDAQ:CYNA) closed on September 19, 2016, at $40.20 per share.
Those who are current investors in NASDAQ:CYNA shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego